PharmAbcine has a well-established innovative discovery system for the human diseases, especially cancers and inflammatory disorders. It holds an its own phage-based fully human IgG library for the discovery of novel therapeutics and has also well-experienced personnel resources. The company is developing a variety of mAbs against various cancer-related target proteins and especially TTAC0001, a lead mAb against VEGFR-2(KDR), is now studying in preclinical stage. PharmAbcine has also an innovative platform technology on next-generation bi-specific mAb and is exploring any cancerous molecular marker using its own cancer stem cell library.

Lead mAb - TTAC0001

TTAC0001, a fully human anti-angiogenic mAb against VEGFR-2, was developed and being studied for application of preclinical study. The antibody showed potent anti-angiogenic efficacy against various cancer-involved experiments as well as cross-species cross reactivity in mouse model. Those characteristics give reasonable promise of being successful as therapeutics. In addition to TTAC0001, a variety of mAbs against various cancer marker were developed and listed in our pipelines. TTAC0001 is now under late stage of preclinical research.

Next-Generation bi-specific mAb - DIG and PIG

Dual specific antibody technologies, DIG and PIG, are being developed for therapeutic use. Those technologies adopted a full IgG format for single therapy, and showed effective efficacy, including synergy effect against different target proteins. Now, DIG0001 and PIG0001 are studying for preparing preclinical study.

Cancer Stem Cell Library

We have
1) a fully established system for solid tumor cancer stem cell isolation
2) fully established various cancer stem cell libraries for research and commercialization
3) fully established cancer stem cell-derived animal models for research and commercialization